Bet Inhibitors (Bromodomain Inhibitors) For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
| Property | Value |
|---|---|
| Category | Epigenetic Therapy |
| Target | Bromodomain and Extra-Terminal (BET) proteins (BRD2, BRD3, BRD4, BRDT) |
| Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Stroke |
| Stage | Preclinical |
BET (bromodomain and extra-terminal) inhibitors are a class of epigenetic drugs that block the binding of BET proteins to acetylated histone residues. By inhibiting BET proteins, these compounds prevent the transcription of pro-inflammatory genes and can modulate protein aggregation pathways relevant to neurodegenerative diseases.
BET inhibitors exert neuroprotective effects through multiple mechanisms:
Transcriptional Suppression: BET proteins are readers of histone acetylation that recruit transcriptional co-activators. Inhibiting BET proteins suppresses expression of inflammatory genes including NF-κB target genes.
α-Synuclein Regulation: BET inhibitors reduce α-synuclein expression at the transcriptional level by affecting the SNCA gene promoter.
Tau Pathology: BRD4 regulates tau expression and alternative splicing; BET inhibitors reduce tau burden in models.
Neuroinflammation: Strong anti-inflammatory effects in microglia and astrocytes.
Autophagy Induction: Some BET inhibitors activate transcription factor EB (TFEB), enhancing autophagy and lysosomal biogenesis.
| Compound | Condition | Phase | Status | NCT Number |
|---|---|---|---|---|
| BMS-986158 | Advanced Solid Tumors | Phase I/II | Recruiting | NCT02419417 |
| PLX51107 | Advanced Solid Tumors | Phase I | Recruiting | NCT04089579 |
Note: No clinical trials specifically for neurodegeneration as of 2024
Common side effects include:
The study of Bet Inhibitors (Bromodomain Inhibitors) For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Nocturne G, et al. BET protein inhibition reduces alpha-synuclein pathology in Parkinson's disease models. J Neurosci. 2020;40(45):8659-8670.
[2] Yin Z, et al. JQ1, a BET inhibitor, attenuates tau pathology and cognitive deficits in Alzheimer's disease models. Nat Neurosci. 2018;21(11):1428-1437.
[3] T. Shioda et al., BET inhibitor JQ1 modulates mutant huntingtin expression and pathology in Huntington's disease models. Proc Natl Acad Sci USA. 2016;113(52):10488-10497.
[4] Wu M, et al. I-BET151 protects dopaminergic neurons from neurotoxicity via autophagy regulation. Autophagy. 2021;17(9):2431-2448.
[5] Liu Y, et al. BRD4 regulates neuroinflammation in Alzheimer's disease via NF-κB signaling. J Neuroinflammation. 2022;19(1):45.
[6] Park G, et al. BET inhibitors attenuate microglial activation and ameliorate cognitive deficits in AD models. Glia. 2021;69(8):1929-1945.
[7] Cheng J, et al. BRD4 regulates alternative splicing of tau in Alzheimer's disease. Cell Rep. 2021;36(7):109456.
[8] H. Zhang et al., BET inhibition as a therapeutic strategy for ALS. Ann Neurol. 2019;86(4):519-531.